Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Amylyx Pharmaceuticals, Inc. - Common Stock (NQ: AMLX ) 2.020 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jul 19, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 530 Open 2.020 Bid (Size) 1.920 (1) Ask (Size) 1.990 (7) Prev. Close 2.020 Today's Range 2.020 - 2.020 52wk Range 1.575 - 25.48 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Analyst Ratings For Amylyx Pharma July 12, 2024 Via Benzinga NVIDIA To Rally More Than 33%? Here Are 10 Top Analyst Forecasts For Friday July 12, 2024 Via Benzinga Performance YTD -86.51% -86.51% 1 Month +13.48% +13.48% 3 Month +2.02% +2.02% 6 Month -86.25% -86.25% 1 Year -91.19% -91.19% More News Read More Why Is Small Cap Amylyx Pharmaceuticals Stock Trading Higher On Wednesday? July 10, 2024 Via Benzinga Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation July 10, 2024 From Amylyx Pharmaceuticals, Inc. Via Business Wire 6 Analysts Assess Amylyx Pharma: What You Need To Know June 24, 2024 Via Benzinga Breaking Down Amylyx Pharma: 9 Analysts Share Their Views May 10, 2024 Via Benzinga Unveiling 6 Analyst Insights On Amylyx Pharma April 08, 2024 Via Benzinga Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide July 09, 2024 From Amylyx Pharmaceuticals, Inc. Via Business Wire Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference June 04, 2024 From Amylyx Pharmaceuticals, Inc. Via Business Wire AMLX Stock Earnings: Amylyx Pharma Misses EPS, Misses Revenue for Q1 2024 May 09, 2024 Via InvestorPlace Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results May 09, 2024 From Amylyx Pharmaceuticals, Inc. Via Business Wire Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference May 08, 2024 From Amylyx Pharmaceuticals, Inc. Via Business Wire Amylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024 May 02, 2024 From Amylyx Pharmaceuticals, Inc. Via Business Wire Amylyx Pharmaceuticals' Investigational Drug Shows Improved Pancreatic Function In Patients With Inherited Disorder April 10, 2024 Via Benzinga Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome April 10, 2024 From Amylyx Pharmaceuticals, Inc. Via Business Wire AMLX DEADLINE TOMORROW: TOP RANKED ROSEN LAW FIRM Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX April 08, 2024 Via NewMediaWire Topics Lawsuit Exposures Financial Legal AMLX DEADLINE TOMORROW: TOP RANKED ROSEN LAW FIRM Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX April 08, 2024 Via TheNewswire.com Topics Lawsuit Exposures Financial Legal The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. (AMLX) April 08, 2024 From The Law Offices of Frank R. Cruz Via Business Wire AMLX DEADLINE TOMORROW: ROSEN, LEADING INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action – AMLX April 08, 2024 From The Rosen Law Firm PA Via GlobeNewswire Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024 April 08, 2024 From Amylyx Pharmaceuticals, Inc. Via Business Wire AMLX IMPORTANT DEADLINE: ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX April 07, 2024 Via NewMediaWire Topics Lawsuit Exposures Financial Legal AMLX IMPORTANT DEADLINE: ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX April 07, 2024 Via TheNewswire.com Topics Lawsuit Exposures Financial Legal AMLX DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX April 06, 2024 Via NewMediaWire Topics Lawsuit Exposures Financial Legal AMLX DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX April 06, 2024 Via TheNewswire.com Topics Lawsuit Exposures Financial Legal AMLX DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX April 05, 2024 Via NewMediaWire Topics Lawsuit Exposures Financial Legal Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.